OR WAIT null SECS
The first program of this collaboration will focus on the development of a candidate for severe acute pancreatitis.
Samsung Bioepis announced on Aug. 21, 2017 that it has teamed up with Takeda to jointly fund and co-develop novel biologics for unmet disease areas. Both companies will immediately begin working on the program’s first candidate, TAK-671, intended to treat severe acute pancreatitis. The risk-sharing collaboration brings together Samsung Bioepis’ biologics development platform with Takeda’s expertise in drug development. Other terms of the agreement were not disclosed.
“Five years ago, we entered the biopharmaceutical industry with a strong determination to transform the way therapies are brought to patients by replacing legacy processes with new and innovative ones. Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, commented in a press statement.
“At Takeda, we think differently and creatively about what makes a partnership successful and look to build on our strengths by collaborating with partners who have complementary expertise,” Daniel Curran, head of Takeda’s Center for External Innovation said in the press release. “This collaboration with Samsung Bioepis does that; by combining our unique capabilities in development and manufacturing along with fresh and innovative clinical approaches, we will maximize the potential for successful introduction of important medicines to patients.”
Source: Samsung Bioepis